Capmatinib is primarily indicated for patients with MET exon 14 skipping mutations in non-small cell lung cancer (NSCLC). This mutation is found in a small subset of NSCLC patients and is associated with poorer prognosis. The presence of this specific mutation can be identified using genetic testing, making it a targeted therapy that is personalized to the patient's genetic profile.
